<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02124330</url>
  </required_header>
  <id_info>
    <org_study_id>RC 06-13</org_study_id>
    <secondary_id>RC 06/13</secondary_id>
    <nct_id>NCT02124330</nct_id>
  </id_info>
  <brief_title>Protein Sorbent Properties of Montmorillonite in Vitro and in Vivo Models</brief_title>
  <official_title>Protein Sorbent Properties of Montmorillonite in Vitro and in Vivo Models</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luca Ronfani</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Trieste</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IRCCS Burlo Garofolo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Montmorillonite (MONT) is a phyllosilicate layered mineral with unique physicochemical
      properties, such as swelling and cation exchange capability.

      The aim of this project is to study, in healthy volunteers, the in vivo ability of MONT to
      reduce protein intestinal uptake. Furthermore, the study analyzed in vitro the MONT ability
      of immobilizing proteins.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Montmorillonite (MONT) is a phyllosilicate layered mineral; chemically it is hydrated sodium
      calcium aluminium magnesium silicate hydroxide. Potassium, iron, and other cations are common
      substitutes and the exact ratio of cations varies with source.

      Due to its unique physicochemical properties, such as swelling and cation exchange
      capability, as well its mechanical and thermal stability, MONT can be efficiently used as
      matrix for immobilization of proteins with high molecular weight (e.g. Albumin) and proteins
      with low molecular weight (e.g.Aflatoxines). Therefore, MONT is used for therapeutic
      purposes, in pharmaceutical formulations and in food preparations. In vitro assays made in
      our laboratory, showed that MONT absorbs, in stable manner, alimentary proteins:
      beta-lactoglobulins, alfa lactoalbumines and the ratio MONT-protein (w/w) 1:3, 1:5, 1:15,
      results in the protein capture of 50, 27, 0 % of proteins respectively.

      The aim of this project is to study, in healthy volunteers, the in vivo ability of MONT to
      reduce protein intestinal uptake evaluated with the blood MONT- protein ratio. Furthermore,
      the study analyzed in vitro the MONT ability of immobilizing proteins at different ratio
      (w/w) 1:3, 1:5, 1:15.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2013</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Protein uptake evaluated with the blood MONT-protein ratio</measure>
    <time_frame>before administration and 30, 60, 90, 120 ,180 minutes after</time_frame>
    <description>A solution of MONT and whey protein dissolved in 200 ml of water at the three different ratios will be administered. The control group will intake 15g of protein alone.
Blood samples will be centrifuged and analyzed by mass spectrometry (egilent HP5973 mass spectrometry).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Protein absorption by MONT in vitro</measure>
    <time_frame>at time of the trial</time_frame>
    <description>MONT and protein (whey protein) at three different ratio w/w (1:3, 1:5, 1:15) will be dissolved in acetate buffer 0.1M pH5 as well as a sample without MONT.
Samples will incubate at RT for 1, 10, 30, 60 minutes and then centrifugate at 13000g.
The surnatant will be analyzed by LOWRY method. Protein concentration will be expressed in mg/ml. The MONT ability of immobilization will be calculated respect to the protein control sample</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Urea Cycle Disorders, Inborn</condition>
  <condition>Other Metabolic Diseases</condition>
  <arm_group>
    <arm_group_label>montmorillonite 5 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5g Montmorillonite + 15 g protein (ratio 1:3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Montmorillonite 3 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3g Montmorillonite + 15 g protein (ratio 1:5)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Montmorillonite 1 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1g Montmorillonite + 15 g protein (ratio 1:15)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>A control goup will intake 15 g of protein alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>montmorillonite 5 g</intervention_name>
    <description>5g montmorillonite + 15 g protein (ratio 1:3)</description>
    <arm_group_label>montmorillonite 5 g</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>montmorillonite 3 g</intervention_name>
    <description>3g MONT+ 15 g protein (ratio 1:5)</description>
    <arm_group_label>Montmorillonite 3 g</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Montmorillonite 1 g</intervention_name>
    <description>1g MONT+ 15 g protein (ratio 1:15)</description>
    <arm_group_label>Montmorillonite 1 g</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy volunteers (12M, 13 F, 25-30 years). Fasting from morning

        Exclusion Criteria:

          -  not defined
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tarcisio Not, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Maternal and Child Health IRCCS Burlo Garofolo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute for Maternal and Child Health IRCCS Burlo Garofolo</name>
      <address>
        <city>Trieste</city>
        <state>Friuli Venezia Giulia</state>
        <zip>34137</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2013</study_first_submitted>
  <study_first_submitted_qc>April 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2014</study_first_posted>
  <last_update_submitted>March 8, 2017</last_update_submitted>
  <last_update_submitted_qc>March 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Burlo Garofolo</investigator_affiliation>
    <investigator_full_name>Luca Ronfani</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Montmorillonite, proteic diet, in vitro and in vivo models</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Urea Cycle Disorders, Inborn</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bentonite</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

